According to Inotiv's latest financial reports the company's current revenue (TTM) is $0.58 B. In 2022 the company made a revenue of $0.58 B an increase over the years 2021 revenue that were of $0.15 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.58 B | -0.18% |
2022 | $0.58 B | 275.94% |
2021 | $0.15 B | 138.29% |
2020 | $65.43 M | 36.58% |
2019 | $47.9 M | 61.89% |
2018 | $29.59 M | 26.23% |
2017 | $23.44 M | 7.94% |
2016 | $21.72 M | -0.13% |
2015 | $21.74 M | -10.17% |
2014 | $24.2 M | 7.67% |
2013 | $22.48 M | -15.14% |
2012 | $26.49 M | -18.65% |
2011 | $32.57 M | 6.81% |
2010 | $30.49 M | 1.36% |
2009 | $30.08 M | -24.67% |
2008 | $39.93 M | -9.36% |
2007 | $44.06 M | -0.06% |
2006 | $44.08 M | 3.62% |
2005 | $42.54 M | 11.76% |
2004 | $38.06 M | 20.31% |
2003 | $31.64 M | 15.21% |
2002 | $27.46 M | 6.15% |
2001 | $25.87 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Nymox Pharmaceutical NYMX | N/A | N/A | Bahamas |
NRC Health
NRC | $0.14 B | -74.61% | ๐บ๐ธ USA |